Abstract Details
Erica McKenzie, MD
(University of Calgary, Department of Clinical Neurosciences)
PRESENTER |
Dr. McKenzie has nothing to disclose. |
No disclosure on file | |
No disclosure on file | |
No disclosure on file | |
No disclosure on file | |
No disclosure on file | |
Sydney Cash, MD (Massachusetts General Hospital) | Dr. Cash has received stock or an ownership interest from Beacon Biosignals. |
Ronald L. Thibert, DO | Dr. Thibert has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Ovid Pharmaceuticals. |
Rodrigo Zepeda, MD (University of Texas Southwestern) | The institution of Dr. Zepeda has received research support from NIH. |
Edward C. Leung, MD (Health Sciences Centre) | No disclosure on file |
Alice D. Lam, MD, PhD | Dr. Lam has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Neurona Therapeutics. Dr. Lam has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Acadia Pharmaceuticals. The institution of Dr. Lam has received research support from Neurona Therapeutics. |
Andrew Lim, MD (Univ Toronto / Lim and Hew Med Prof Corp) | Dr. Lim has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Eisai Canada. |
No disclosure on file | |
No disclosure on file | |
Andrew Cole, MD, FAAN (Massachusetts General Hospital) | Dr. Cole has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Medtronic. Dr. Cole has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for ANA. Dr. Cole has received publishing royalties from a publication relating to health care. |
Farrah J. Mateen, MD, PhD, FAAN (Massachusetts General Hospital) | Dr. Mateen has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Horizon Therapeutics (Amgen). Dr. Mateen has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genentech. Dr. Mateen has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for EMD Serono. Dr. Mateen has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Neurology. The institution of Dr. Mateen has received research support from Genentech. The institution of Dr. Mateen has received research support from EMD Serono. The institution of Dr. Mateen has received research support from Novartis. The institution of Dr. Mateen has received research support from Horizon Therapeutics (Amgen). The institution of Dr. Mateen has received research support from TG Therapeutics. Dr. Mateen has received intellectual property interests from a discovery or technology relating to health care. |